The effect of teritolumab (Teclistamab-cqyv) in the treatment of multiple myeloma

Teritusumab (Teclistamab-cqyv) has shown encouraging therapeutic effects in the treatment of multiple myeloma (MM), especially providing new treatment hope for relapsed or refractory patients. As a bispecific antibody, it simultaneously targets CD3 on T cells and BCMA on the surface of myeloma cells, effectively activating T cells in the immune system to directly kill tumor cells, thus breaking the problem of high dependence of traditional treatment methods on the immune system and filling the treatment gap after immune tolerance or relapse.

In multiple overseas key clinical trials, teritolumab has been proven to have a higher response rate and longer disease control time in myeloma patients who have failed to respond to multiple front-line treatments. Its mechanism avoids the limitations of relying on tumor cell expression of antigens or the integrity of the MHC pathway, making it still effective in patients with multiple lines of treatment failure and complex mutations. This immune-redirecting treatment mode is considered the "fourth mode" of myeloma treatment, an important addition after chemotherapy, targeted and monoclonal antibody treatments.

In addition to its advantages in efficacy, teritusumab also has the characteristic of rapid onset of action. Some patients can see positive signals such as a decrease in protein levels in a short period of time, indicating a rapid reduction in tumor burden. Although cytokine release syndrome (CRS) or other immune side effects may occur during treatment, these problems can be well controlled under hospital management, and pretreatment strategies are currently available to reduce their severity.

The advent of teritolumab marks a new era of precision immunotherapy for multiple myeloma. Although the drug is not yet popular worldwide, its rapid promotion and patient feedback in the European and American markets have laid the foundation for its future widespread use in Asia, including the Chinese market. For patients who have repeatedly relapsed in traditional regimens, teritolumab is undoubtedly a new option worth looking forward to.

Reference materials:https://www.tecvayli.com/